These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 17577792)

  • 21. Successful management of liver injury caused by imatinib mesylate in a patient with previously untreated chronic myelogenous leukemia in the chronic phase.
    Yamazaki R; Okamoto S; Chen CK; Tada S; Saito H; Shibata R; Sakamoto M; Mori T; Ikeda Y
    Leuk Lymphoma; 2006 Jul; 47(7):1427-30. PubMed ID: 16923586
    [No Abstract]   [Full Text] [Related]  

  • 22. Sustained superior long-term outcomes and cytogenetic responses with imatinib mesylate in chronic phase chronic myeloid leukaemia: report from a developing country.
    Aziz Z; Iqbal J; Bano K; Faisal M; Akram M
    Jpn J Clin Oncol; 2010 Jun; 40(6):549-55. PubMed ID: 20189974
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [A clinical study of treating 120 cases of adult chronic myelocytic leukemia with imatinib mesylate].
    Chen ZC; You Y; Zhu XM; Li QB; Li WM; Zou P
    Zhonghua Nei Ke Za Zhi; 2007 Dec; 46(12):1003-6. PubMed ID: 18478917
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imatinib-induced immune hepatitis: case report and literature review.
    Al Sobhi E; Zahrani Z; Zevallos E; Zuraiki A
    Hematology; 2007 Feb; 12(1):49-53. PubMed ID: 17364993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clonal evolution in Philadelphia chromosome negative cells following successful treatment with Imatinib of a CML patient: clinical and biological features of a myelodysplastic syndrome.
    Alimena G; Breccia M; Mancini M; Ferranti G; De Felice L; Gallucci C; Mandelli F
    Leukemia; 2004 Feb; 18(2):361-2. PubMed ID: 14614517
    [No Abstract]   [Full Text] [Related]  

  • 26. Concomitant myelodysplastic syndrome and chronic myeloid leukaemia: treatment outcomes with imatinib mesylate.
    Mesa RA; Steensma DP; Hoyer J; Ketterling RP
    Br J Haematol; 2003 Oct; 123(2):366-7. PubMed ID: 14531922
    [No Abstract]   [Full Text] [Related]  

  • 27. Imatinib-induced optic neuritis in a patient of chronic myeloid leukemia.
    Govind Babu K; Attili VS; Bapsy PP; Anupama G
    Int Ophthalmol; 2007 Feb; 27(1):43-4. PubMed ID: 17410337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic lymphocytic leukaemia developing in the course of chronic myeloid leukaemia.
    Salim R; Wang L; Lin K; Clark RE
    Leuk Lymphoma; 2002 Nov; 43(11):2225-7. PubMed ID: 12533052
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Imatinib: a review of its use in chronic myeloid leukaemia.
    Moen MD; McKeage K; Plosker GL; Siddiqui MA
    Drugs; 2007; 67(2):299-320. PubMed ID: 17284091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Philadelphia-negative acute promyelocytic leukemia in a patient with chronic myeloid leukemia in complete cytogenetic response after treatment with tyrosine kinase inhibitor.
    Inokura K; Onishi Y; Shimosegawa K; Okitsu Y; Katsuoka Y; Fujiwara T; Fukuhara N; Ishizawa K; Harigae H
    Ann Hematol; 2012 Nov; 91(11):1825-6. PubMed ID: 22543830
    [No Abstract]   [Full Text] [Related]  

  • 31. Spotlight on imatinib mesylate in chronic myeloid leukemia.
    Curran MP; Croom KF; Goa KL
    BioDrugs; 2004; 18(3):207-10. PubMed ID: 15161340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospective single-center study of chronic myeloid leukemia in chronic phase: switching from branded imatinib to a copy drug and back.
    Alwan AF; Matti BF; Naji AS; Muhammed AH; Abdulsahib MA
    Leuk Lymphoma; 2014 Dec; 55(12):2830-4. PubMed ID: 24628295
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imatinib mesylate induced immune thrombocytopenia.
    Rajappa S; Varadpande L; Paul TR; Digumarti R
    Leuk Lymphoma; 2007 Nov; 48(11):2261-3. PubMed ID: 17926182
    [No Abstract]   [Full Text] [Related]  

  • 34. Safety and efficacy of nilotinib in chronic phase chronic myeloid leukemia in a patient with Wolf-Parkinson-White disease and hematological resistance after suboptimal response to imatinib at six months.
    Cannella L; Breccia M; Loglisci G; Federico V; Santopietro M; Alimena G
    Acta Oncol; 2010 Apr; 49(3):399-400. PubMed ID: 20105089
    [No Abstract]   [Full Text] [Related]  

  • 35. Trisomy 8 in Philadelphia chromosome negative cell preceding the evolution of a Philadelphia chromosome positive clone with the same additional change during imatinib treatment: revisiting the role of genetic instability in chronic myeloid leukemia.
    Cannella L; Loglisci G; Nanni M; De Cuia MR; Colafigli G; Salaroli A; Serrao A; Alimena G; Breccia M
    Leuk Lymphoma; 2012 Mar; 53(3):497-8. PubMed ID: 21854086
    [No Abstract]   [Full Text] [Related]  

  • 36. A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (STI 571, Glivec).
    Drummond A; Micallef-Eynaud P; Douglas WS; Hay I; Holyoake TL; Drummond MW
    Br J Haematol; 2003 Mar; 120(5):911-3. PubMed ID: 12614232
    [No Abstract]   [Full Text] [Related]  

  • 37. Imatinib therapy for patients with chronic myelogenous leukemia: are patients living longer?
    DeAngelo DJ; Ritz J
    Clin Cancer Res; 2004 Jan; 10(1 Pt 1):1-3. PubMed ID: 14734443
    [No Abstract]   [Full Text] [Related]  

  • 38. Secondary malignancy after imatinib therapy: eight cases and review of the literature.
    Duman BB; Paydas S; Disel U; Besen A; Gurkan E
    Leuk Lymphoma; 2012 Sep; 53(9):1706-8. PubMed ID: 22329351
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Deleterious effects of non-branded versions of imatinib used for the treatment of patients with chronic myeloid leukemia in chronic phase: a case series on an escalating issue impacting patient safety.
    Saavedra D; Vizcarra F
    Leuk Lymphoma; 2014 Dec; 55(12):2813-6. PubMed ID: 24724785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia.
    Schwarz M; Kreuzer KA; Baskaynak G; Dörken B; le Coutre P
    Eur J Haematol; 2002 Oct; 69(4):254-6. PubMed ID: 12431246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.